Home / Prices / Intravitreal aflibercept injection

Intravitreal aflibercept injection

Eye Care estimated about CNY 6000-7500

Disclaimer: This site is a medical service platform; some page content is AI-assisted. Health-related information does not constitute medical advice. If you have any questions, please consult a healthcare professional. See full disclaimer

Description

A standard ophthalmic procedure involving injection of the anti-VEGF drug aflibercept into the vitreous cavity to treat neovascular age-related macular degeneration, diabetic retinopathy, and macular edema.

Main Uses

Primary clinical use is the treatment of neovascular (wet) age-related macular degeneration (nAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and myopic choroidal neovascularization (mCNV). Administered via sterile intravitreal injection every 4–8 weeks initially, then extended based on disease activity assessed by optical coherence tomography (OCT), fundus examination, and best-corrected visual acuity (BCVA). It functions by binding and neutralizing VEGF-A and Placental Growth Factor (PlGF), thereby inhibiting pathological angiogenesis and vascular leakage.

Normal Range

Not applicable — anti-VEGF intravitreal injection (aflibercept) is a therapeutic procedure, not a diagnostic laboratory test with quantitative 'values' or reference ranges. There is no 'normal range' for aflibercept concentration in clinical practice; dosing is standardized (2 mg/0.05 mL per injection) and guided by anatomical/functional response (e.g., OCT-measured retinal thickness, visual acuity), not serum or intraocular drug level thresholds.

Low Values - Possible Causes

N/A — 'Low value' is not clinically meaningful for this intervention. However, suboptimal treatment response (e.g., persistent fluid on OCT or vision loss despite injection) may result from: 1) Inadequate dosing frequency or interval extension beyond evidence-based regimens; 2) Poor patient adherence to follow-up visits; 3) Development of anti-drug antibodies (rare); 4) Underlying disease severity or resistance (e.g., chronic fibrosis, RPE atrophy); 5) Concomitant uncontrolled systemic conditions (e.g., hypertension, diabetes).

High Values - Possible Causes

N/A — 'High value' does not apply, as aflibercept is not measured quantitatively in routine care. Potential risks associated with excessive or inappropriate use include: 1) Increased intraocular pressure spikes post-injection; 2) Cumulative intraocular inflammation or sterile endophthalmitis; 3) Accelerated cataract progression; 4) Rare systemic thromboembolic events (theoretical VEGF inhibition effect); 5) Retinal pigment epithelium (RPE) tears in eyes with large pigment epithelial detachments.

intravitreal injection aflibercept anti-VEGF therapy

estimated about CNY 6000-7500